Metabolic syndrome.
Journal
Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103
Informations de publication
Date de publication:
17 Oct 2024
17 Oct 2024
Historique:
accepted:
17
09
2024
medline:
18
10
2024
pubmed:
18
10
2024
entrez:
17
10
2024
Statut:
epublish
Résumé
The metabolic syndrome (MetS) is a multiplex modifiable risk factor for cardiovascular disease, type 2 diabetes mellitus and other health outcomes, and is a major challenge to clinical practice and public health. The rising global prevalence of MetS, driven by urbanization, sedentary lifestyles and dietary changes, underlines the urgency of addressing this syndrome. We explore the complex underlying mechanisms, including genetic predisposition, insulin resistance, accumulation of dysfunctional adipose tissue and ectopic lipids in abdominal obesity, systemic inflammation and dyslipidaemia, and how they contribute to the clinical manifestations of MetS. Diagnostic approaches vary but commonly focus on abdominal obesity (assessed using waist circumference), hyperglycaemia, dyslipidaemia and hypertension, highlighting the need for population-specific and phenotype-specific diagnostic strategies. Management of MetS prioritizes lifestyle modifications, such as healthy dietary patterns, physical activity and management of excess visceral and ectopic adiposity, as foundational interventions. We also discuss emerging therapies, including new pharmacological treatments and surgical options, providing a forward-looking perspective on MetS research and care. This Primer aims to inform clinicians, researchers and policymakers about MetS complexities, advocating for a cohesive, patient-centred management and prevention strategy. Emphasizing the multifactorial nature of MetS, this Primer calls for integrated public health efforts, personalized care and innovative research to address this escalating health issue.
Identifiants
pubmed: 39420195
doi: 10.1038/s41572-024-00563-5
pii: 10.1038/s41572-024-00563-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
77Informations de copyright
© 2024. Springer Nature Limited.
Références
Reaven, G. M. Why syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab. 1, 9–14 (2005).
pubmed: 16054040
doi: 10.1016/j.cmet.2004.12.001
Despres, J. P. & Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 444, 881–887 (2006). A paper outlining that the most prevalent form of the metabolic syndrome is found among individuals with excess visceral adipose tissue and ectopic fat.
pubmed: 17167477
doi: 10.1038/nature05488
Despres, J. P. et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol. 28, 1039–1049 (2008).
pubmed: 18356555
doi: 10.1161/ATVBAHA.107.159228
Reaven, G. M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595–1607 (1988).
pubmed: 3056758
doi: 10.2337/diab.37.12.1595
Alberti, K. G. & Zimmet, P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539–553 (1998).
pubmed: 9686693
doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
Balkau, B. & Charles, M. A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet. Med. 16, 442–443 (1999).
pubmed: 10342346
doi: 10.1046/j.1464-5491.1999.00059.x
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001).
doi: 10.1001/jama.285.19.2486
Hagberg, C. E. & Spalding, K. L. White adipocyte dysfunction and obesity-associated pathologies in humans. Nat. Rev. Mol. Cell Biol. 25, 270–289 (2024). An update on the function and roles of white adipocytes in human diseases.
pubmed: 38086922
doi: 10.1038/s41580-023-00680-1
Grundy, S. M. et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433–438 (2004).
pubmed: 14744958
doi: 10.1161/01.CIR.0000111245.75752.C6
Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009). The most contemporary definition of the metabolic syndrome and rationale for the definition.
pubmed: 19805654
doi: 10.1161/CIRCULATIONAHA.109.192644
Sperling, L. S. et al. The Cardiometabolic Health Alliance: working toward a new care model for the metabolic syndrome. J. Am. Coll. Cardiol. 66, 1050–1067 (2015). A discussion of the strategy and intervention for the metabolic syndrome from a joint cardiovascular and endocrinological perspective.
pubmed: 26314534
doi: 10.1016/j.jacc.2015.06.1328
Ndumele, C. E. et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation 148, 1636–1664 (2023).
pubmed: 37807920
doi: 10.1161/CIR.0000000000001186
Alberti, K. G., Zimmet, P. & Shaw, J. The metabolic syndrome – a new worldwide definition. Lancet 366, 1059–1062 (2005).
pubmed: 16182882
doi: 10.1016/S0140-6736(05)67402-8
Bloomgarden, Z. T. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care 26, 1297–1303 (2003).
pubmed: 12663612
doi: 10.2337/diacare.26.4.1297
Grundy, S. M. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735–2752 (2005).
pubmed: 16157765
doi: 10.1161/CIRCULATIONAHA.105.169404
Liang, X., Or, B., Tsoi, M. F., Cheung, C. L. & Cheung, B. M. Y. Prevalence of metabolic syndrome in the United States National Health and Nutrition Examination Survey 2011-18. Postgrad. Med. J. 99, 985–992 (2023).
pubmed: 36906842
doi: 10.1093/postmj/qgad008
Dev, R. et al. Impact of sex and gender on metabolic syndrome in adults: a retrospective cohort study from the Canadian Primary Care Sentinel Surveillance Network. Can. J. Diabetes 99, 36–43.e2 (2023).
Perez-Castro, E., Godinez-Jaimes, F., Vazquez-Medina, M. U., Ocharan-Hernandez, M. E. & Vargas-De-Leon, C. Derivation and validation of sex-specific continuous metabolic syndrome scores for the Mexican adult population. Sci. Rep. 12, 9659 (2022).
pubmed: 35688913
pmcid: 9187334
doi: 10.1038/s41598-022-10963-w
Vishram, J. K. et al. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project. PLoS ONE 9, e107294 (2014).
pubmed: 25244618
pmcid: 4171109
doi: 10.1371/journal.pone.0107294
Cen, M. et al. Associations between metabolic syndrome and anxiety, and the mediating role of inflammation: findings from the UK Biobank. Brain Behav. Immun. 116, 1–9 (2023).
pubmed: 37984624
doi: 10.1016/j.bbi.2023.11.019
Yamazaki, Y. et al. Usefulness of new criteria for metabolic syndrome optimized for prediction of cardiovascular diseases in Japanese. J. Atheroscler. Thromb. 31, 382–395 (2024).
pubmed: 37981330
doi: 10.5551/jat.64380
Park, D. et al. 20-year trends in metabolic syndrome among Korean adults from 2001 to 2020. JACC Asia 3, 491–502 (2023).
pubmed: 37396427
pmcid: 10308107
doi: 10.1016/j.jacasi.2023.02.007
Yang, S. et al. Development and validation of an age-sex-ethnicity-specific metabolic syndrome score in the Chinese adults. Nat. Commun. 14, 6988 (2023).
pubmed: 37914709
pmcid: 10620391
doi: 10.1038/s41467-023-42423-y
Ramachandran, A., Snehalatha, C., Satyavani, K., Sivasankari, S. & Vijay, V. Metabolic syndrome in urban Asian Indian adults – a population study using modified ATP III criteria. Diabetes Res. Clin. Pract. 60, 199–204 (2003).
pubmed: 12757982
doi: 10.1016/S0168-8227(03)00060-3
Krishnamoorthy, Y. et al. Prevalence of metabolic syndrome among adult population in India: a systematic review and meta-analysis. PLoS ONE 15, e0240971 (2020).
pubmed: 33075086
pmcid: 7571716
doi: 10.1371/journal.pone.0240971
Bowo-Ngandji, A. et al. Prevalence of the metabolic syndrome in African populations: a systematic review and meta-analysis. PLoS ONE 18, e0289155 (2023).
pubmed: 37498832
pmcid: 10374159
doi: 10.1371/journal.pone.0289155
Asgedom, Y. S. et al. Prevalence of metabolic syndrome among people living with human immunodeficiency virus in sub-Saharan Africa: a systematic review and meta-analysis. Sci. Rep. 14, 11709 (2024).
pubmed: 38777850
pmcid: 11111734
doi: 10.1038/s41598-024-62497-y
Tagi, V. M., Samvelyan, S. & Chiarelli, F. Treatment of metabolic syndrome in children. Horm. Res. Paediatr. 93, 215–225 (2020).
pubmed: 33017828
doi: 10.1159/000510941
Reisinger, C., Nkeh-Chungag, B. N., Fredriksen, P. M. & Goswami, N. The prevalence of pediatric metabolic syndrome – a critical look on the discrepancies between definitions and its clinical importance. Int. J. Obes. 45, 12–24 (2021). A critical discussion of issues relevant to the metabolic sydrome in the paediatric population.
doi: 10.1038/s41366-020-00713-1
Noubiap, J. J. et al. Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. Lancet Child. Adolesc. Health 6, 158–170 (2022).
pubmed: 35051409
doi: 10.1016/S2352-4642(21)00374-6
Messiah, S. E. et al. Prevalence of the metabolic syndrome by household food insecurity status in the United States adolescent population, 2001-2020: a cross-sectional study. Am. J. Clin. Nutr. 119, 354–361 (2023).
pubmed: 38042411
doi: 10.1016/j.ajcnut.2023.11.014
Choi, J. E. et al. Increase of prevalence of obesity and metabolic syndrome in children and adolescents in Korea during the COVID-19 pandemic: a cross-sectional study using the KNHANES. Children 10, 1105 (2023).
pubmed: 37508602
pmcid: 10378374
doi: 10.3390/children10071105
Varhlunchungi, V. et al. Metabolic syndrome among adolescents aged 10–19 years in India: a systematic review and meta-analysis. Cureus 15, e48636 (2023).
pubmed: 38090460
pmcid: 10711264
Cook, S., Weitzman, M., Auinger, P., Nguyen, M. & Dietz, W. H. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch. Pediatr. Adolesc. Med. 157, 821–827 (2003).
pubmed: 12912790
doi: 10.1001/archpedi.157.8.821
Cheng, X. et al. Association between sedentary behavior, screen time and metabolic syndrome among Chinese children and adolescents. BMC Public. Health 24, 1715 (2024).
pubmed: 38937700
pmcid: 11210024
doi: 10.1186/s12889-024-19227-w
Tchernof, A. & Despres, J. P. Pathophysiology of human visceral obesity: an update. Physiol. Rev. 93, 359–404 (2013). A comprehensive review of the role of excess visceral adiposity as a key driver of cardiometabolic risk.
pubmed: 23303913
doi: 10.1152/physrev.00033.2011
Neeland, I. J. et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity 21, E439–E447 (2012).
Yaskolka Meir, A. et al. Intrahepatic fat, abdominal adipose tissues, and metabolic state: magnetic resonance imaging study. Diabetes Metab. Res. Rev. 33, e2888 (2017).
Saponaro, C. et al. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals. Liver Int. 42, 2418–2427 (2022). A paper showing that individuals with non-alcoholic steatohepatitis have increased VAT that is associated with insulin resistance in liver, muscle and adipose tissue, increased lipolysis and decreased adiponectin levels.
pubmed: 35900229
doi: 10.1111/liv.15377
Gepner, Y. et al. Intramyocellular triacylglycerol accumulation across weight loss strategies; sub-study of the CENTRAL trial. PLoS ONE 12, e0188431 (2017).
pubmed: 29190720
pmcid: 5708655
doi: 10.1371/journal.pone.0188431
Choe, H. J., Chang, W., Bluher, M., Heymsfield, S. B. & Lim, S. Independent association of thigh muscle fat density with vascular events in Korean adults. Cardiovasc. Diabetol. 23, 44 (2024).
pubmed: 38281946
pmcid: 10823598
doi: 10.1186/s12933-024-02138-w
Roh, E. et al. Comparison of pancreatic volume and fat amount linked with glucose homeostasis between healthy Caucasians and Koreans. Diabetes Obes. Metab. 20, 2642–2652 (2018).
pubmed: 29934972
doi: 10.1111/dom.13447
Zelicha, H. et al. Changes of renal sinus fat and renal parenchymal fat during an 18-month randomized weight loss trial. Clin. Nutr. 37, 1145–1153 (2018).
pubmed: 28501343
doi: 10.1016/j.clnu.2017.04.007
Kim, T. H. et al. Pericardial fat amount is an independent risk factor of coronary artery stenosis assessed by multidetector-row computed tomography: the Korean Atherosclerosis Study 2. Obesity 19, 1028–1034 (2011).
pubmed: 20948524
doi: 10.1038/oby.2010.246
Chin, J. F. et al. Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity. Eur. J. Heart Fail. 25, 1936–1943 (2023).
pubmed: 37642195
doi: 10.1002/ejhf.3011
Chen, O. et al. Correlation between pericardial, mediastinal, and intrathoracic fat volumes with the presence and severity of coronary artery disease, metabolic syndrome, and cardiac risk factors. Eur. Heart J. Cardiovasc. Imaging 16, 37–46 (2015).
pubmed: 25227267
doi: 10.1093/ehjci/jeu145
Tsaban, G. et al. Dynamics of intrapericardial and extrapericardial fat tissues during long-term, dietary-induced, moderate weight loss. Am. J. Clin. Nutr. 106, 984–995 (2017).
pubmed: 28814394
doi: 10.3945/ajcn.117.157115
Sironi, A. M. et al. Impact of increased visceral and cardiac fat on cardiometabolic risk and disease. Diabet. Med. 29, 622–627 (2012).
pubmed: 22023514
doi: 10.1111/j.1464-5491.2011.03503.x
Piche, M. E., Tchernof, A. & Despres, J. P. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ. Res. 126, 1477–1500 (2020). A proposal to move discussions from obesity as a single disorder to obesities (that is, obesity phenotypes).
pubmed: 32437302
doi: 10.1161/CIRCRESAHA.120.316101
Bilson, J. et al. Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD. Metabolism 151, 155759 (2023).
pubmed: 38101770
doi: 10.1016/j.metabol.2023.155759
Michaud, A. et al. Relevance of omental pericellular adipose tissue collagen in the pathophysiology of human abdominal obesity and related cardiometabolic risk. Int. J. Obes. 40, 1823–1831 (2016).
doi: 10.1038/ijo.2016.173
Laforest, S., Labrecque, J., Michaud, A., Cianflone, K. & Tchernof, A. Adipocyte size as a determinant of metabolic disease and adipose tissue dysfunction. Crit. Rev. Clin. Lab. Sci. 52, 301–313 (2015).
pubmed: 26292076
doi: 10.3109/10408363.2015.1041582
Michaud, A., Drolet, R., Noel, S., Paris, G. & Tchernof, A. Visceral fat accumulation is an indicator of adipose tissue macrophage infiltration in women. Metabolism 61, 689–698 (2012).
pubmed: 22154325
doi: 10.1016/j.metabol.2011.10.004
Harman-Boehm, I. et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J. Clin. Endocrinol. Metab. 92, 2240–2247 (2007).
pubmed: 17374712
doi: 10.1210/jc.2006-1811
Rosendo-Silva, D. et al. Clinical and molecular profiling of human visceral adipose tissue reveals impairment of vascular architecture and remodeling as an early hallmark of dysfunction. Metabolism 153, 155788 (2024).
pubmed: 38219974
doi: 10.1016/j.metabol.2024.155788
Rosso, C. et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J. Hepatol. 71, 1012–1021 (2019). Altered adipose tissue metabolism is associated with macrophage activity in MASLD, independent of obesity and diabetes mellitus, probably due to FFA spillover from adipose tissue.
pubmed: 31301321
doi: 10.1016/j.jhep.2019.06.031
Bouchard, C. et al. The response to long-term overfeeding in identical twins. N. Engl. J. Med. 322, 1477–1482 (1990). A seminal intervention study documenting that susceptibility to visceral versus subcutaneous adipose tissue deposition has a genetic basis.
pubmed: 2336074
doi: 10.1056/NEJM199005243222101
Thomas, D. G., Wei, Y. & Tall, A. R. Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study. J. Lipid Res. 62, 100044 (2021).
pubmed: 32907989
pmcid: 7933489
doi: 10.1194/jlr.P120001000
He, Q. et al. Genetic insights into the risk of metabolic syndrome and its components on stroke and its subtypes: bidirectional Mendelian randomization. J. Cereb. Blood Flow. Metab. 43, 126–137 (2023).
pubmed: 37198928
pmcid: 10638990
doi: 10.1177/0271678X231169838
Xia, L. et al. A Mendelian randomization study between metabolic syndrome and its components with prostate cancer. Sci. Rep. 14, 14338 (2024).
pubmed: 38906920
pmcid: 11192917
doi: 10.1038/s41598-024-65310-y
Gao, X. et al. Genetic evidence for the causal relations between metabolic syndrome and psychiatric disorders: a Mendelian randomization study. Transl. Psychiatry 14, 46 (2024).
pubmed: 38245519
pmcid: 10799927
doi: 10.1038/s41398-024-02759-5
Marc, J. Genetic succeptibility to metabolic syndrome. EJIFCC 18, 7–14 (2007).
pubmed: 29632462
pmcid: 5875076
McCarthy, J. J. et al. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum. Genet. 114, 87–98 (2003).
pubmed: 14557872
doi: 10.1007/s00439-003-1026-1
Xiao, Z. & Liu, H. The estrogen receptor and metabolism. Womens Health 20, 17455057241227362 (2024).
Tchernof, A. et al. Androgens and the regulation of adiposity and body fat distribution in humans. Compr. Physiol. 8, 1253–1290 (2018).
pubmed: 30215860
doi: 10.1002/cphy.c170009
Starcke, S. & Vollmer, G. Is there an estrogenic component in the metabolic syndrome. Genes. Nutr. 1, 177–188 (2006).
pubmed: 18850213
pmcid: 3454834
doi: 10.1007/BF02829967
Cherubini, A. et al. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. Nat. Med. 29, 2643–2655 (2023).
pubmed: 37749332
pmcid: 10579099
doi: 10.1038/s41591-023-02553-8
White, U. & Ravussin, E. Dynamics of adipose tissue turnover in human metabolic health and disease. Diabetologia 62, 17–23 (2019).
pubmed: 30267179
doi: 10.1007/s00125-018-4732-x
Lim, S. & Meigs, J. B. Links between ectopic fat and vascular disease in humans. Arterioscler. Thromb. Vasc. Biol. 34, 1820–1826 (2014).
pubmed: 25035342
pmcid: 4140970
doi: 10.1161/ATVBAHA.114.303035
Rosito, G. A. et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 117, 605–613 (2008).
pubmed: 18212276
doi: 10.1161/CIRCULATIONAHA.107.743062
Ding, J. et al. Association between non-subcutaneous adiposity and calcified coronary plaque: a substudy of the Multi-Ethnic Study of Atherosclerosis. Am. J. Clin. Nutr. 88, 645–650 (2008).
pubmed: 18779279
doi: 10.1093/ajcn/88.3.645
Wu, Y., Zhang, A., Hamilton, D. J. & Deng, T. Epicardial fat in the maintenance of cardiovascular health. Methodist. Debakey Cardiovasc. J. 13, 20–24 (2017).
pubmed: 28413578
pmcid: 5385790
doi: 10.14797/mdcj-13-1-20
Thanassoulis, G. et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ. Arrhythm. Electrophysiol. 3, 345–350 (2010).
pubmed: 20558845
pmcid: 2953855
doi: 10.1161/CIRCEP.109.912055
Lamacchia, O. et al. Para- and perirenal fat thickness is an independent predictor of chronic kidney disease, increased renal resistance index and hyperuricaemia in type-2 diabetic patients. Nephrol. Dial. Transpl. 26, 892–898 (2011).
doi: 10.1093/ndt/gfq522
Guo, X. L., Wang, J. W., Tu, M. & Wang, W. Perirenal fat thickness as a superior obesity-related marker of subclinical carotid atherosclerosis in type 2 diabetes mellitus. Front. Endocrinol. 14, 1276789 (2023).
doi: 10.3389/fendo.2023.1276789
Bosy-Westphal, A., Braun, W., Albrecht, V. & Muller, M. J. Determinants of ectopic liver fat in metabolic disease. Eur. J. Clin. Nutr. 73, 209–214 (2019).
pubmed: 30323174
doi: 10.1038/s41430-018-0323-7
Montastier, E. et al. Increased postprandial nonesterified fatty acid efflux from adipose tissue in prediabetes is offset by enhanced dietary fatty acid adipose trapping. Am. J. Physiol. Endocrinol. Metab. 320, E1093–E1106 (2021).
pubmed: 33870714
doi: 10.1152/ajpendo.00619.2020
Couillard, C. et al. Postprandial triglyceride response in visceral obesity in men. Diabetes 47, 953–960 (1998).
pubmed: 9604874
doi: 10.2337/diabetes.47.6.953
Carpentier, A. C., Labbé, S. M., Grenier-Larouche, T. & Noll, C. Abnormal dietary fatty acid metabolic partitioning in insulin resistance and type 2 diabetes. Clin. Lipidol. 6, 703–716 (2013).
doi: 10.2217/clp.11.60
Spalding, K. L. et al. Dynamics of fat cell turnover in humans. Nature 453, 783–787 (2008).
pubmed: 18454136
doi: 10.1038/nature06902
Virtue, S. & Vidal-Puig, A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome – an allostatic perspective. Biochim. Biophys. Acta 1801, 338–349 (2010).
pubmed: 20056169
doi: 10.1016/j.bbalip.2009.12.006
Arner, E. et al. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes 59, 105–109 (2010).
pubmed: 19846802
doi: 10.2337/db09-0942
Iacobini, C., Vitale, M., Haxhi, J., Menini, S. & Pugliese, G. Impaired remodeling of white adipose tissue in obesity and aging: from defective adipogenesis to adipose organ dysfunction. Cells 13, 763 (2024).
pubmed: 38727299
pmcid: 11083890
doi: 10.3390/cells13090763
Lessard, J. et al. Low abdominal subcutaneous preadipocyte adipogenesis is associated with visceral obesity, visceral adipocyte hypertrophy, and a dysmetabolic state. Adipocyte 3, 197–205 (2014).
pubmed: 25068086
pmcid: 4110096
doi: 10.4161/adip.29385
Gastaldelli, A. et al. PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver Int. 41, 2659–2670 (2021).
pubmed: 34219361
pmcid: 9290929
doi: 10.1111/liv.15005
Hammarstedt, A., Gogg, S., Hedjazifar, S., Nerstedt, A. & Smith, U. Impaired adipogenesis and dysfunctional adipose tissue in human hypertrophic obesity. Physiol. Rev. 98, 1911–1941 (2018). A comprehensive review of the role of impaired adipogenesis as a primary defect leading to increased cardiometabolic risk.
pubmed: 30067159
doi: 10.1152/physrev.00034.2017
Gustafson, B., Nerstedt, A. & Smith, U. Reduced subcutaneous adipogenesis in human hypertrophic obesity is linked to senescent precursor cells. Nat. Commun. 10, 2757 (2019).
pubmed: 31227697
pmcid: 6588633
doi: 10.1038/s41467-019-10688-x
Rouault, C. et al. Senescence-associated β-galactosidase in subcutaneous adipose tissue associates with altered glycaemic status and truncal fat in severe obesity. Diabetologia 64, 240–254 (2021).
pubmed: 33125520
doi: 10.1007/s00125-020-05307-0
Smith, U., Li, Q., Ryden, M. & Spalding, K. L. Cellular senescence and its role in white adipose tissue. Int. J. Obes. 45, 934–943 (2021).
doi: 10.1038/s41366-021-00757-x
Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542–1556 (2023). The new definition of MASLD, which now includes steatosis plus at least one feature of the metabolic syndrome, especially steatosis with increased waist circumference.
pubmed: 37364790
doi: 10.1016/j.jhep.2023.06.003
Liu, J. et al. Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler. Thromb. Vasc. Biol. 31, 2715–2722 (2011).
pubmed: 21885852
pmcid: 3228266
doi: 10.1161/ATVBAHA.111.234062
Chen, Y.-l et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 21, 212 (2021).
pubmed: 33971822
pmcid: 8111711
doi: 10.1186/s12876-021-01782-w
Adiels, M. et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49, 755–765 (2006).
pubmed: 16463046
doi: 10.1007/s00125-005-0125-z
Hodson, L. et al. The contribution of splanchnic fat to VLDL triglyceride is greater in insulin-resistant than insulin-sensitive men and women: studies in the postprandial state. Diabetes 56, 2433–2441 (2007).
pubmed: 17601988
doi: 10.2337/db07-0654
Boden, G., Chen, X., Capulong, E. & Mozzoli, M. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes 50, 810–816 (2001).
pubmed: 11289046
doi: 10.2337/diabetes.50.4.810
Stefan, N. et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57, 2762–2767 (2008).
pubmed: 18633113
pmcid: 2551687
doi: 10.2337/db08-0538
Peter, A. et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am. J. Physiol. Endocrinol. Metab. 314, E266–E273 (2018).
pubmed: 29138227
doi: 10.1152/ajpendo.00262.2017
Mindur, J. E. & Swirski, F. K. Growth factors as immunotherapeutic targets in cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 39, 1275–1287 (2019).
pubmed: 31092009
pmcid: 6613384
doi: 10.1161/ATVBAHA.119.311994
Gaggini, M. et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 5, 1544–1560 (2013).
pubmed: 23666091
pmcid: 3708335
doi: 10.3390/nu5051544
Tejani, S. et al. Cardiometabolic health outcomes associated with discordant visceral and liver fat phenotypes: insights from the Dallas Heart Study and UK Biobank. Mayo Clin. Proc. 97, 225–237 (2022).
pubmed: 34598789
doi: 10.1016/j.mayocp.2021.08.021
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G. & Barbui, C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J. Hepatol. 65, 589–600 (2016).
pubmed: 27212244
doi: 10.1016/j.jhep.2016.05.013
Lauridsen, B. K. et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. Eur. Heart J. 39, 385–393 (2018).
pubmed: 29228164
doi: 10.1093/eurheartj/ehx662
Klein, S., Gastaldelli, A., Yki-Jarvinen, H. & Scherer, P. E. Why does obesity cause diabetes? Cell Metab. 34, 11–20 (2022). This review discusses the complex cellular and physiological mechanisms responsible for the link between obesity and T2DM, which involve adiposity-induced alterations in β-cell function, adipose tissue biology and multi-organ insulin resistance.
pubmed: 34986330
pmcid: 8740746
doi: 10.1016/j.cmet.2021.12.012
DeFronzo, R. A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53, 1270–1287 (2010).
pubmed: 20361178
pmcid: 2877338
doi: 10.1007/s00125-010-1684-1
Brehm, A. et al. Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes 55, 136–140 (2006).
pubmed: 16380486
doi: 10.2337/diabetes.55.01.06.db05-1286
Belfort, R. et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 54, 1640–1648 (2005).
pubmed: 15919784
doi: 10.2337/diabetes.54.6.1640
Gastaldelli, A. et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133, 496–506 (2007).
pubmed: 17681171
doi: 10.1053/j.gastro.2007.04.068
Masoodi, M. et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat. Rev. Gastroenterol. Hepatol. 18, 835–856 (2021).
pubmed: 34508238
doi: 10.1038/s41575-021-00502-9
Magkos, F. et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 142, 1444–1446.e2 (2012).
pubmed: 22425588
doi: 10.1053/j.gastro.2012.03.003
Luukkonen, P. K. et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J. Hepatol. 64, 1167–1175 (2016).
pubmed: 26780287
doi: 10.1016/j.jhep.2016.01.002
Samuel, V. T. & Shulman, G. I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Invest. 126, 12–22 (2016).
pubmed: 26727229
pmcid: 4701542
doi: 10.1172/JCI77812
Stratford, S., Hoehn, K. L., Liu, F. & Summers, S. A. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J. Biol. Chem. 279, 36608–36615 (2004).
pubmed: 15220355
doi: 10.1074/jbc.M406499200
Powell, D. J., Hajduch, E., Kular, G. & Hundal, H. S. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCζ-dependent mechanism. Mol. Cell Biol. 23, 7794–7808 (2003).
pubmed: 14560023
pmcid: 207567
doi: 10.1128/MCB.23.21.7794-7808.2003
Lyu, K. et al. A membrane-bound diacylglycerol species induces PKCε-mediated hepatic insulin resistance. Cell Metab. 32, 654–664.e5 (2020).
pubmed: 32882164
pmcid: 7544641
doi: 10.1016/j.cmet.2020.08.001
Hilvo, M. et al. Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. Eur. Heart J. 41, 371–380 (2020).
pubmed: 31209498
doi: 10.1093/eurheartj/ehz387
Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179–188 (2011).
pubmed: 21217695
pmcid: 3076025
doi: 10.1038/nm.2279
Holland, W. L. et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 17, 55–63 (2011).
pubmed: 21186369
doi: 10.1038/nm.2277
Holland, W. L. et al. Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis. Mol. Metab. 6, 267–275 (2017).
pubmed: 28271033
pmcid: 5323887
doi: 10.1016/j.molmet.2017.01.002
Vijay, J. et al. Single-cell analysis of human adipose tissue identifies depot and disease specific cell types. Nat. Metab. 2, 97–109 (2020).
pubmed: 32066997
doi: 10.1038/s42255-019-0152-6
Lin, D., Chun, T. H. & Kang, L. Adipose extracellular matrix remodelling in obesity and insulin resistance. Biochem. Pharmacol. 119, 8–16 (2016).
pubmed: 27179976
pmcid: 5061598
doi: 10.1016/j.bcp.2016.05.005
Ruiz-Ojeda, F. J., Mendez-Gutierrez, A., Aguilera, C. M. & Plaza-Diaz, J. Extracellular matrix remodeling of adipose tissue in obesity and metabolic diseases. Int. J. Mol. Sci. 20, 4888 (2019).
pubmed: 31581657
pmcid: 6801592
doi: 10.3390/ijms20194888
Divoux, A. et al. Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes 59, 2817–2825 (2010).
pubmed: 20713683
pmcid: 2963540
doi: 10.2337/db10-0585
Divoux, A. & Clement, K. Architecture and the extracellular matrix: the still unappreciated components of the adipose tissue. Obes. Rev. 12, e494–e503 (2011).
pubmed: 21366833
doi: 10.1111/j.1467-789X.2010.00811.x
Antoniades, C. et al. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers. Eur. Heart J. 44, 3827–3844 (2023).
pubmed: 37599464
pmcid: 10568001
doi: 10.1093/eurheartj/ehad484
Sun, J. Y., Su, Z., Yang, J., Sun, W. & Kong, X. The potential mechanisms underlying the modulating effect of perirenal adipose tissue on hypertension: physical compression, paracrine, and neurogenic regulation. Life Sci. 342, 122511 (2024).
pubmed: 38387699
doi: 10.1016/j.lfs.2024.122511
Antoniades, C., Antonopoulos, A. S. & Deanfield, J. Imaging residual inflammatory cardiovascular risk. Eur. Heart J. 41, 748–758 (2020).
pubmed: 31317172
doi: 10.1093/eurheartj/ehz474
Hall, J. E. et al. Obesity, kidney dysfunction, and inflammation: interactions in hypertension. Cardiovasc. Res. 117, 1859–1876 (2021).
pubmed: 33258945
doi: 10.1093/cvr/cvaa336
Gaba, P., Gersh, B. J., Muller, J., Narula, J. & Stone, G. W. Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research. Nat. Rev. Cardiol. 20, 181–196 (2023).
pubmed: 36151312
doi: 10.1038/s41569-022-00769-8
Cuspidi, C. et al. Nondipping pattern and carotid atherosclerosis: a systematic review and meta-analysis. J. Hypertens. 34, 385–391 (2016).
pubmed: 26818921
doi: 10.1097/HJH.0000000000000812
Li, M. et al. The pathophysiological associations between obesity, NAFLD, and atherosclerotic cardiovascular diseases. Horm. Metab. Res. https://doi.org/10.1055/a-2266-1503 (2024).
doi: 10.1055/a-2266-1503
pubmed: 39348827
Gallo, G. & Savoia, C. New insights into endothelial dysfunction in cardiometabolic diseases: potential mechanisms and clinical implications. Int. J. Mol. Sci. 25, 2973 (2024).
pubmed: 38474219
pmcid: 10932073
doi: 10.3390/ijms25052973
Luciani, L., Pedrelli, M. & Parini, P. Modification of lipoprotein metabolism and function driving atherogenesis in diabetes. Atherosclerosis 394, 117545 (2024).
pubmed: 38688749
doi: 10.1016/j.atherosclerosis.2024.117545
Moriyama, K. The association between the triglyceride to high-density lipoprotein cholesterol ratio and low-density lipoprotein subclasses. Intern. Med. 59, 2661–2669 (2020).
pubmed: 32669498
pmcid: 7691041
doi: 10.2169/internalmedicine.4954-20
Silveira Rossi, J. L. et al. Metabolic syndrome and cardiovascular diseases: going beyond traditional risk factors. Diabetes Metab. Res. Rev. 38, e3502 (2022).
pubmed: 34614543
doi: 10.1002/dmrr.3502
Masenga, S. K., Kabwe, L. S., Chakulya, M. & Kirabo, A. Mechanisms of oxidative stress in metabolic syndrome. Int. J. Mol. Sci. 24, 7898 (2023).
pubmed: 37175603
pmcid: 10178199
doi: 10.3390/ijms24097898
Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606–1635 (2023).
pubmed: 37807924
doi: 10.1161/CIR.0000000000001184
Rangaswami, J. et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 139, e840–e878 (2019).
pubmed: 30852913
doi: 10.1161/CIR.0000000000000664
Einhorn, D. et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9, 237–252 (2003).
pubmed: 12924350
doi: 10.4158/EP.9.S2.5
Neeland, I. J. et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 7, 715–725 (2019). A key position statement describing the link between visceral adipose tissue and ectopic fat, and cardiometabolic disease.
pubmed: 31301983
doi: 10.1016/S2213-8587(19)30084-1
Gami, A. S. et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 49, 403–414 (2007).
pubmed: 17258085
doi: 10.1016/j.jacc.2006.09.032
Neeland, I. J., Yokoo, T., Leinhard, O. D. & Lavie, C. J. 21st century advances in multimodality imaging of obesity for care of the cardiovascular patient. JACC Cardiovasc. Imaging 14, 482–494 (2021).
pubmed: 32305476
doi: 10.1016/j.jcmg.2020.02.031
van Walree, E. S. et al. Disentangling genetic risks for metabolic syndrome. Diabetes 71, 2447–2457 (2022).
pubmed: 35983957
doi: 10.2337/db22-0478
Hsu, N. W. et al. Building a model for predicting metabolic syndrome using artificial intelligence based on an investigation of whole-genome sequencing. J. Transl. Med. 20, 190 (2022).
pubmed: 35484552
pmcid: 9052619
doi: 10.1186/s12967-022-03379-7
Benmohammed, K., Valensi, P., Omri, N., Al Masry, Z. & Zerhouni, N. Metabolic syndrome screening in adolescents: new scores AI_METS based on artificial intelligence techniques. Nutr. Metab. Cardiovasc. Dis. 32, 2890–2899 (2022).
pubmed: 36182336
doi: 10.1016/j.numecd.2022.08.007
Neeland, I. J., Poirier, P. & Despres, J. P. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation 137, 1391–1406 (2018). A review article describing the heterogeneous manifestations and health complications related to obesity.
pubmed: 29581366
pmcid: 5875734
doi: 10.1161/CIRCULATIONAHA.117.029617
Despres, J. P. et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler. Thromb. Vasc. Biol. 20, 1932–1938 (2000).
pubmed: 10938014
doi: 10.1161/01.ATV.20.8.1932
Warburton, D. E., Charlesworth, S., Ivey, A., Nettlefold, L. & Bredin, S. S. A systematic review of the evidence for Canada’s Physical Activity Guidelines for Adults. Int. J. Behav. Nutr. Phys. Act. 7, 39 (2010).
pubmed: 20459783
pmcid: 3583166
doi: 10.1186/1479-5868-7-39
Broekhuizen, L. N. et al. Physical activity, metabolic syndrome, and coronary risk: the EPIC-Norfolk prospective population study. Eur. J. Cardiovasc. Prev. Rehabil. 18, 209–217 (2011).
pubmed: 21450666
doi: 10.1177/1741826710389397
Eilat-Adar, S. et al. Dietary patterns and their association with cardiovascular risk factors in a population undergoing lifestyle changes: the Strong Heart Study. Nutr. Metab. Cardiovasc. Dis. 23, 528–535 (2013).
pubmed: 22534653
doi: 10.1016/j.numecd.2011.12.005
Estruch, R. et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J. Med. 368, 1279–1290 (2013).
pubmed: 23432189
doi: 10.1056/NEJMoa1200303
Mozaffarian, D., Appel, L. J. & Van Horn, L. Components of a cardioprotective diet: new insights. Circulation 123, 2870–2891 (2011).
pubmed: 21690503
pmcid: 6261290
doi: 10.1161/CIRCULATIONAHA.110.968735
Alexander, C. M. et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52, 1210–1214 (2003).
pubmed: 12716754
doi: 10.2337/diabetes.52.5.1210
Rubino, F. et al. Lancet Diabetes & Endocrinology Commission on the definition and diagnosis of clinical obesity. Lancet Diabetes Endocrinol. 11, 226–228 (2023).
pubmed: 36878238
doi: 10.1016/S2213-8587(23)00058-X
Busetto, L. et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat. Med. 20, 2395–2399 (2024).
doi: 10.1038/s41591-024-03095-3
Rao, S. et al. Effect of exercise and pharmacological interventions on visceral adiposity: a systematic review and meta-analysis of long-term randomized controlled trials. Mayo Clin. Proc. 94, 211–224 (2019).
pubmed: 30711119
doi: 10.1016/j.mayocp.2018.09.019
Neeland, I. J. et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 9, 595–605 (2021). The first randomized clinical trial to describe the effects of GLP1 receptor agonists on VAT and ectopic fat in individuals without diabetes mellitus.
pubmed: 34358471
doi: 10.1016/S2213-8587(21)00179-0
Meyer-Gerspach, A. C. et al. Quantification of liver, subcutaneous, and visceral adipose tissues by MRI before and after bariatric surgery. Obes. Surg. 29, 2795–2805 (2019).
pubmed: 31089967
pmcid: 6713693
doi: 10.1007/s11695-019-03897-2
Hanipah, Z. N. & Schauer, P. R. Bariatric surgery as a long-term treatment for type 2 diabetes/metabolic syndrome. Annu. Rev. Med. 71, 1–15 (2020).
pubmed: 31986081
doi: 10.1146/annurev-med-053117-123246
Picot, J. et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol. Assess. https://doi.org/10.3310/hta13410 (2009).
Yu, W., Chen, J., Fan, L., Yan, C. & Zhu, L. Cost-effectiveness of laparoscopic sleeve gastrectomy for Chinese patients. Obes. Surg. 34, 2828–2834 (2024).
pubmed: 38981958
pmcid: 11289027
doi: 10.1007/s11695-024-07330-1
Gallagher, C., Corl, A. & Dietz, W. H. Weight can’t wait: a guide to discussing obesity and organizing treatment in the primary care setting. Obesity 29, 821–824 (2021).
pubmed: 33899338
doi: 10.1002/oby.23154
Wadden, T. A., Tronieri, J. S. & Butryn, M. L. Lifestyle modification approaches for the treatment of obesity in adults. Am. Psychol. 75, 235–251 (2020).
pubmed: 32052997
pmcid: 7027681
doi: 10.1037/amp0000517
Alamuddin, N. & Wadden, T. A. Behavioral treatment of the patient with obesity. Endocrinol. Metab. Clin. North. Am. 45, 565–580 (2016).
pubmed: 27519131
doi: 10.1016/j.ecl.2016.04.008
Lichtenstein, A. H. et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation 144, e472–e487 (2021).
pubmed: 34724806
doi: 10.1161/CIR.0000000000001031
Jensen, M. D. et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129, S102–S138 (2014).
pubmed: 24222017
doi: 10.1161/01.cir.0000437739.71477.ee
Wewege, M. A., Thom, J. M., Rye, K. A. & Parmenter, B. J. Aerobic, resistance or combined training: a systematic review and meta-analysis of exercise to reduce cardiovascular risk in adults with metabolic syndrome. Atherosclerosis 274, 162–171 (2018).
pubmed: 29783064
doi: 10.1016/j.atherosclerosis.2018.05.002
Chomiuk, T., Niezgoda, N., Mamcarz, A. & Sliz, D. Physical activity in metabolic syndrome. Front. Physiol. 15, 1365761 (2024).
pubmed: 38440349
pmcid: 10910017
doi: 10.3389/fphys.2024.1365761
Barone Gibbs, B. et al. Physical activity as a critical component of first-line treatment for elevated blood pressure or cholesterol: who, what, and how?: A scientific statement from the American Heart Association. Hypertension 78, e26–e37 (2021).
pubmed: 34074137
doi: 10.1161/HYP.0000000000000196
Powell-Wiley, T. M. et al. Social determinants of cardiovascular disease. Circ. Res. 130, 782–799 (2022).
pubmed: 35239404
pmcid: 8893132
doi: 10.1161/CIRCRESAHA.121.319811
Gaede, P., Lund-Andersen, H., Parving, H. H. & Pedersen, O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358, 580–591 (2008).
pubmed: 18256393
doi: 10.1056/NEJMoa0706245
Cornier, M. A. et al. The metabolic syndrome. Endocr. Rev. 29, 777–822 (2008).
pubmed: 18971485
pmcid: 5393149
doi: 10.1210/er.2008-0024
Shang, Y. et al. Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes. Diabetes Care 47, 978–985 (2024).
pubmed: 38498331
pmcid: 11116921
doi: 10.2337/dc23-1937
Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
pubmed: 11832527
doi: 10.1056/NEJMoa012512
Jang, H. et al. Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA Intern. Med. 184, 375–383 (2024).
pubmed: 38345802
doi: 10.1001/jamainternmed.2023.8029
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R. & Davies, M. J. Type 2 diabetes. Lancet 400, 1803–1820 (2022).
pubmed: 36332637
doi: 10.1016/S0140-6736(22)01655-5
Moon, J. S. et al. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol. Metab. 33, 424–442 (2022).
pubmed: 35491295
doi: 10.1016/j.tem.2022.03.005
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400, 1788–1801 (2022).
doi: 10.1016/S0140-6736(22)02074-8
Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 (2022).
pubmed: 35658024
doi: 10.1056/NEJMoa2206038
Campbell, J. E. et al. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metab. 35, 1519–1529 (2023).
pubmed: 37591245
pmcid: 10528201
doi: 10.1016/j.cmet.2023.07.010
Rosenstock, J. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398, 143–155 (2021).
pubmed: 34186022
doi: 10.1016/S0140-6736(21)01324-6
Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity – a phase 2 trial. N. Engl. J. Med. 389, 514–526 (2023).
pubmed: 37366315
doi: 10.1056/NEJMoa2301972
Wright, J. T. Jr et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103–2116 (2015).
pubmed: 26551272
doi: 10.1056/NEJMoa1511939
Arnett, D. K. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation 140, e596–e646 (2019).
pubmed: 30879355
pmcid: 7734661
Bhatt, D. L. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med. 380, 11–22 (2019).
pubmed: 30415628
doi: 10.1056/NEJMoa1812792
Gaziano, J. M. et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 392, 1036–1046 (2018).
pubmed: 30158069
pmcid: 7255888
doi: 10.1016/S0140-6736(18)31924-X
McNeil, J. J. et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N. Engl. J. Med. 379, 1509–1518 (2018).
pubmed: 30221597
pmcid: 6289056
doi: 10.1056/NEJMoa1805819
Bowman, L. et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N. Engl. J. Med. 379, 1529–1539 (2018).
pubmed: 30146931
doi: 10.1056/NEJMoa1804988
Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. Collaborative Study Group. N. Engl. J. Med. 329, 1456–1462 (1993).
pubmed: 8413456
doi: 10.1056/NEJM199311113292004
Herrington, W. G. et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117–127 (2023).
pubmed: 36331190
doi: 10.1056/NEJMoa2204233
Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).
pubmed: 32970396
doi: 10.1056/NEJMoa2024816
Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).
pubmed: 33264825
doi: 10.1056/NEJMoa2025845
Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109–121 (2024).
pubmed: 38785209
doi: 10.1056/NEJMoa2403347
Weihe, P. & Weihrauch-Bluher, S. Metabolic syndrome in children and adolescents: diagnostic criteria, therapeutic options and perspectives. Curr. Obes. Rep. 8, 472–479 (2019).
pubmed: 31691175
doi: 10.1007/s13679-019-00357-x
DeBoer, M D. Assessing and managing the metabolic syndrome in children and adolescents. Nutrients 11, 1788 (2019).
pubmed: 31382417
pmcid: 6723651
doi: 10.3390/nu11081788
Ford, E. S. & Li, C. Metabolic syndrome and health-related quality of life among U.S. adults. Ann. Epidemiol. 18, 165–171 (2008).
pubmed: 18280918
doi: 10.1016/j.annepidem.2007.10.009
Lin, Y. H. et al. Changes in metabolic syndrome affect the health-related quality of life of community-dwelling adults. Sci. Rep. 11, 20267 (2021).
pubmed: 34642379
pmcid: 8511017
doi: 10.1038/s41598-021-99767-y
Tsai, A. G. et al. Metabolic syndrome and health-related quality of life in obese individuals seeking weight reduction. Obesity 16, 59–63 (2008).
pubmed: 18223613
doi: 10.1038/oby.2007.8
Chen, M. Z., Wong, M. W. K., Lim, J. Y. & Merchant, R. A. Frailty and quality of life in older adults with metabolic syndrome – findings from the Healthy Older People Everyday (HOPE) study. J. Nutr. Health Aging 25, 637–644 (2021).
pubmed: 33949631
doi: 10.1007/s12603-021-1609-3
Limon, V. M., Lee, M., Gonzalez, B., Choh, A. C. & Czerwinski, S. A. The impact of metabolic syndrome on mental health-related quality of life and depressive symptoms. Qual. Life Res. 29, 2063–2072 (2020).
pubmed: 32215841
pmcid: 7513573
doi: 10.1007/s11136-020-02479-5
Marcos-Delgado, A. et al. Health-related quality of life in individuals with metabolic syndrome: a cross-sectional study. Semergen 46, 524–537 (2020).
pubmed: 32540410
doi: 10.1016/j.semerg.2020.03.003
Okosun, I. S., Annor, F., Esuneh, F. & Okoegwale, E. E. Metabolic syndrome and impaired health-related quality of life and in non-Hispanic White, non-Hispanic Blacks and Mexican-American Adults. Diabetes Metab. Syndr. 7, 154–160 (2013).
pubmed: 23953181
doi: 10.1016/j.dsx.2013.06.007
Vetter, M. L. et al. Relation of health-related quality of life to metabolic syndrome, obesity, depression and comorbid illnesses. Int. J. Obes. 35, 1087–1094 (2011).
doi: 10.1038/ijo.2010.230
Wang, Q., Chair, S. Y. & Wong, E. M. The effects of a lifestyle intervention program on physical outcomes, depression, and quality of life in adults with metabolic syndrome: a randomized clinical trial. Int. J. Cardiol. 230, 461–467 (2017).
pubmed: 28040281
doi: 10.1016/j.ijcard.2016.12.084
Yadav, R., Yadav, R. K., Pandey, R. M. & Upadhyay, A. D. Predictors of health-related quality of life in Indians with metabolic syndrome undergoing randomized controlled trial of yoga-based lifestyle intervention vs dietary intervention. Behav. Med. 47, 151–160 (2021).
pubmed: 31743071
doi: 10.1080/08964289.2019.1683711
Jeon, J. S. et al. Temporal changes of metabolic indicators and quality of life by a two-day patient education program for metabolic syndrome patients. Int. J. Environ. Res. Public Health 19, 3351 (2022).
pubmed: 35329038
pmcid: 8951422
doi: 10.3390/ijerph19063351
Marcos-Delgado, A., Hernandez-Segura, N., Fernandez-Villa, T., Molina, A. J. & Martin, V. The effect of lifestyle intervention on health-related quality of life in adults with metabolic syndrome: a meta-analysis. Int. J. Environ. Res. Public Health 18, 887 (2021).
pubmed: 33498570
pmcid: 7908372
doi: 10.3390/ijerph18030887
Emery, J. et al. Management of common clinical problems experienced by survivors of cancer. Lancet 399, 1537–1550 (2022).
pubmed: 35430021
doi: 10.1016/S0140-6736(22)00242-2
Despres, J. P., Carpentier, A. C., Tchernof, A., Neeland, I. J. & Poirier, P. Management of obesity in cardiovascular practice: JACC focus seminar. J. Am. Coll. Cardiol. 78, 513–531 (2021).
pubmed: 34325840
pmcid: 8609918
doi: 10.1016/j.jacc.2021.05.035
Neeland, I. J. et al. Second-year results from CINEMA: a novel, patient-centered, team-based intervention for patients with type 2 diabetes or prediabetes at high cardiovascular risk. Am. J. Prev. Cardiol. 17, 100630 (2024).
pubmed: 38223296
doi: 10.1016/j.ajpc.2023.100630
Ross, R. et al. Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR working group on visceral obesity. Nat. Rev. Endocrinol. 16, 177–189 (2020).
pubmed: 32020062
pmcid: 7027970
doi: 10.1038/s41574-019-0310-7
Gastaldelli, A. & Cusi, K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 1, 312–328 (2019).
pubmed: 32039382
pmcid: 7001557
doi: 10.1016/j.jhepr.2019.07.002
Mantovani, A. et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 6, 903–913 (2021).
pubmed: 34555346
doi: 10.1016/S2468-1253(21)00308-3
Kim, K. S., Hong, S., Han, K. & Park, C. Y. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ 384, e076388 (2024).
pubmed: 38350680
pmcid: 10862140
doi: 10.1136/bmj-2023-076388
Fu, C. E. et al. The prognostic value of including non-alcoholic fatty liver disease in the definition of metabolic syndrome. Aliment. Pharmacol. Ther. 57, 979–987 (2023).
pubmed: 36710531
doi: 10.1111/apt.17397
Ramo, J. T. et al. Cardiovascular significance and genetics of epicardial and pericardial adiposity. JAMA Cardiol. 9, 418–427 (2024).
pubmed: 38477908
doi: 10.1001/jamacardio.2024.0080
Khan, S. S. et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation 148, 1982–2004 (2023). This AHA scientific statement describes the rationale behind the development of the new AHA PREVENT equation for predicting total cardiovascular disease risk in individuals with CKM syndrome.
pubmed: 37947094
doi: 10.1161/CIR.0000000000001191
Liao, C., Liang, X., Zhang, X. & Li, Y. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis. PLoS ONE 18, e0289616 (2023).
pubmed: 37616255
pmcid: 10449217
doi: 10.1371/journal.pone.0289616
Gastaldelli, A. et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 10, 393–406 (2022). Clinical trial documenting the effects of dual GIP and GLP1 agonists on visceral adiposity and liver fat content.
pubmed: 35468325
doi: 10.1016/S2213-8587(22)00070-5
Kadowaki, T. et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 10, 193–206 (2022).
pubmed: 35131037
doi: 10.1016/S2213-8587(22)00008-0
Ward, Z. J. et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N. Engl. J. Med. 381, 2440–2450 (2019).
pubmed: 31851800
doi: 10.1056/NEJMsa1909301
WHO Consultation on Obesity. Obesity: preventing and managing the global epidemic: report of a WHO consultation. WHO Technical Report Series 894 (WHO, 2000).
Zhou, B. F., Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults – study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed. Env. Sci. 15, 83–96 (2002).
Tham, K. W. et al. Obesity in South and Southeast Asia – a new consensus on care and management. Obes. Rev. 24, e13520 (2023).
pubmed: 36453081
doi: 10.1111/obr.13520
Health Promotion Administration, Ministry of Health and Welfare. 2016 Annual Report of Health Administration. Health Promotion Administration https://www.hpa.gov.tw/Pages/ashx/File.ashx?FilePath=~/File/Attach/7085/File_6404.pdf (2016).
Misra, A. et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J. Assoc. Physicians India 57, 163–170 (2009).
pubmed: 19582986
Examination Committee of Criteria for ‘Obesity Disease’ in Japan; Japan Society for the Study of, Obesity. New criteria for ‘obesity disease’ in Japan. Circ. J. 66, 987–992 (2002).
doi: 10.1253/circj.66.987
Yang, Y. S. et al. Obesity fact sheet in Korea, 2021: trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J. Obes. Metab. Syndr. 31, 169–177 (2022).
pubmed: 35770450
pmcid: 9284570
doi: 10.7570/jomes22024
Centre for Health Protection. Body mass index chart. Centre for Health Protection https://www.chp.gov.hk/en/resources/e_health_topics/pdfwav_11012.html (2019).
Tobias, M., Paul, S. & Turley, M. Tracking the obesity epidemic: New Zealand 1977–2003. Ministry of Health https://www.health.govt.nz/system/files/2011-11/trackingtheobesityepidemic.pdf (2004).
Ntuk, U. E., Gill, J. M., Mackay, D. F., Sattar, N. & Pell, J. P. Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK biobank participants. Diabetes Care 37, 2500–2507 (2014).
pubmed: 24974975
doi: 10.2337/dc13-2966
Misra, A., Wasir, J. S. & Vikram, N. K. Waist circumference criteria for the diagnosis of abdominal obesity are not applicable uniformly to all populations and ethnic groups. Nutrition 21, 969–976 (2005).
pubmed: 15993041
doi: 10.1016/j.nut.2005.01.007
Haam, J. H. et al. Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity. J. Obes. Metab. Syndr. 32, 121–129 (2023).
pubmed: 37386771
pmcid: 10327686
doi: 10.7570/jomes23031